Phase III Trial of the Safety and Efficacy of Eflornithine Combined With Sulindac Compared to Eflornithine, Sulindac as Single Agents in Patients With Familial Adenomatous Polyposis

Trial Profile

Phase III Trial of the Safety and Efficacy of Eflornithine Combined With Sulindac Compared to Eflornithine, Sulindac as Single Agents in Patients With Familial Adenomatous Polyposis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Eflornithine (Primary) ; Sulindac
  • Indications Familial adenomatous polyposis
  • Focus Registrational; Therapeutic Use
  • Sponsors Cancer Prevention Pharmaceuticals
  • Most Recent Events

    • 18 Jul 2017 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
    • 18 Jul 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
    • 12 Jun 2017 According to a Cancer Prevention Pharmaceuticals media release, an Independent Data Monitoring Committee (IDMC), following a planned interim futility analysis, recommended continuation of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top